EP3340990
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
24.8.2016EP published:
25.9.2019EP application number:
16763585.3
EPO information:
European Patent Register
Max expiry date:
23.8.2036
Title:
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER
Timeline
Today
24.8.2016EP application
25.9.2019EP Publication
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
CAPONIGRO, GiordanoAddress:
Cambridge, Massachusetts, US
Name:
HORN-SPIROHN, ThomasAddress:
Cambridge, Massachusetts, US
Name:
LEHAR, JosephAddress:
Cambridge, Massachusetts, US
Priority
Number:
201562211031 PDate:
28.8.2015Country:
US
Classification
Categories:
A61K 31/517, A61K 31/519, A61P 35/00